RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy.
RNA encoding the human serotonin 5-HT2C receptor (5-HT(2C)R) undergoes adenosine-to-inosine RNA editing events at five positions, resulting in an alteration of amino acids in the second intracellular loop. Several edited 5-HT(2C)Rs possess a reduced G-protein coupling efficiency compared to the completely non-edited isoform. The current studies show that the efficacy of the hallucinogenic drug lysergic acid diethylamide and of antipsychotic drugs is regulated by RNA editing, suggesting that alterations in editing efficiencies or patterns might result in the generation of a 5-HT(2C)R population differentially responsive to serotonergic drugs. An examination of the efficiencies of RNA editing of the 5-HT(2C)R in prefrontal cortex of control individuals vs. subjects diagnosed with schizophrenia or major depressive disorder revealed no significant differences in RNA editing among the three populations. However, subjects who had committed suicide (regardless of diagnosis) exhibited a statistically significant elevation of editing at the A-site, which is predicted to change the amino acid sequence in the second intracellular loop of the 5-HT(2C)R. These findings suggest that alterations in RNA editing may contribute to or complicate therapy in certain psychiatric disorders.
Niswender
C M
CM
Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA.
Herrick-Davis
K
K
Dilley
G E
GE
Meltzer
H Y
HY
Overholser
J C
JC
Stockmeier
C A
CA
Emeson
R B
RB
Sanders-Bush
E
E
D000328:Adult; D000595:Amino Acid Sequence / Q000235:genetics; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D019556:COS Cells / Q000187:drug effects / Q000378:metabolism; D003866:Depressive Disorder / Q000235:genetics / Q000378:metabolism; D005260:Female; D006801:Humans; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism*; D020033:Protein Isoforms / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D017393:RNA Editing / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics* / Q000378:metabolism; D044405:Receptor, Serotonin, 5-HT2C; D011985:Receptors, Serotonin / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology; D012701:Serotonin / Q000235:genetics* / Q000378:metabolism; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D013405:Suicide
D014150:Antipsychotic Agents; D020033:Protein Isoforms; D012333:RNA, Messenger; D044405:Receptor, Serotonin, 5-HT2C; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D012701:Serotonin; D008238:Lysergic Acid Diethylamide